412 studies found for:    Open Studies | "Myelodysplastic Syndromes"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Myelodysplastic Syndromes"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome
Interventions: Drug: Azacitidine;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Decitabine;   Drug: Idarubicin;   Other: Quality-of-Life Assessment
2 Recruiting Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
3 Recruiting Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Myelodysplastic Syndrome With Isolated Del(5q);   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: Sirolimus;   Drug: Azacitidine
4 Recruiting Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions: Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: Filgrastim;   Drug: Mitoxantrone Hydrochloride;   Drug: Cladribine;   Drug: Cytarabine
5 Recruiting Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Drug: Deferasirox placebo
6 Recruiting Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: decitabine;   Drug: cytarabine
7 Recruiting Efficacy and Safety Study of CC-486 (ORAL AZACITIDINE) in Subjects With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: CC-486 (ORAL AZACITIDINE)
8 Unknown  Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)
Condition: Myelodysplastic Syndromes
Intervention: Drug: Darbepoetin
9 Unknown  Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome
Intervention: Drug: AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)
10 Recruiting Study of DSP-7888 in Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: DSP-7888
11 Recruiting Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)
Conditions: Leukemia;   Myelodysplastic Syndrome
Intervention: Behavioral: Interview
12 Not yet recruiting Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Conditions: Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Nivolumab;   Drug: Ipilimumab;   Drug: 5-azacitidine
13 Unknown  Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: Bortezomib
14 Unknown  5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Azacitidine
15 Recruiting Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients
Condition: Myelodysplastic Syndrome
Intervention: Drug: Antibiotic and antifungal drugs
16 Unknown  Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: 5-Azacytidine and Lenalidomide
17 Recruiting Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Radiation: Iodine I 131 Monoclonal Antibody BC8;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
18 Unknown  Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy
Condition: Myelodysplastic Syndrome
Interventions: Drug: BSC;   Drug: HIDRA/VPA
19 Unknown  Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Genetic: DNA methylation analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis
20 Unknown  Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Conditions: Hemochromatosis;   Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Other: Venesection

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years